CEO Michael Heltzen at the Beryl Elite's 'AI in Life Sciences' panel
heltzeninvestorpress clippings
Beryl Elites: AI's Billion-dollar Bet on Life Sciences - From Drug Discovery to Patient Impact (panel)December 15, 2025
100× scale-up of NCT production achieved
press releaseinvestornutraceuticalsmedicine
eXoZymes achieves 100× scale-up of NCT production using exozymes, demonstrating near-perfect feedstock conversionDecember 11, 2025
Vanity Fair: Inside NCTx - How A Rare Plant-Derived Molecule Is Turning Fat Into A Boost Of Energy
nutraceuticalsmedicinepress clippings
Vanity Fair: Inside NCTx - How A Rare Plant-Derived Molecule Is Turning Fat Into A Boost Of EnergyNovember 26, 2025
Fast Company: eXoZymes permite producir compuestos antes imposibles de fabricar gracias a la IA
press clippings
Fast Company: eXoZymes permite producir compuestos antes imposibles de fabricar gracias a la IANovember 21, 2025
LA Weekly: The Enzyme Frontier: eXoZymes Unlocks a New Era for Cannabinoid Nutraceuticals and Pharma
investornutraceuticalsmedicinepress clippings
LA Weekly: The Enzyme Frontier - eXoZymes Unlocks a New Era for Cannabinoid Nutraceuticals and PharmaNovember 20, 2025
Slack Capital report
investorpress clippings
Slack Capital report: EXOZ is a once-in-a-lifetime opportunityNovember 19, 2025
'The Upside' interview: Michael Heltzen & Lou Basenese
heltzeninvestornutraceuticalsmedicinepress clippingsvideo
'The Upside' interview: Michael Heltzen & Lou BaseneseNovember 18, 2025
Transcript: EXOZ Q3 2025 update
investor
Transcript: EXOZ Q3 2025 updateNovember 14, 2025
EXOZ 2025 Q3 Update
press releaseinvestor
eXoZymes provides third quarter 2025 update at 5PM EST todayNovember 13, 2025
CSO Tyler Korman - and Chief of Staff, Amy Lunzer
talentpress releaseinvestor
eXoZymes announces cell-free biomanufacturing pioneer, Tyler Korman, as CSO & Amy Lunzer as Chief of StaffNovember 13, 2025
Previous page
Page 2 of 11
Next page